Monitoring Immune Response Against SARS-CoV-2 Antigens

Monitoring Immune Response Against SARS-CoV-2 Antigens

Development and Optimization of an IFN-γ ELISpot Assay to Monitor Immune Response Against SARS-CoV-2 Antigens

The unprecedented and rapid spread of SARS-CoV2 into a global pandemic, combined with its high mutation rate, has motivated the need for robust vaccines that provide broad protective immunity. As a marker for vaccine activity, ELISpot assays permits detection of low frequency IFN-γ secreting Tcells in response to specific antigens. In addition, ELISpot assays may be used to monitor treatment-specific humoral and cellular immune response in large molecule drug development, which must be closely monitored for safety and efficacy in both clinical and nonclinical studies. Despite of the potential of ELISpot assays, implementation in regulated environments brings new and unique challenges, including a lack of regulatory guidance and gold standard reference materials. Here we present method development and optimization for an IFN-γ ELISpot assay in a regulated environment, demonstrating the value of the assay to support SARS-CoV-2 vaccine development.

Read our expert presentation:

aaps-360-poster-t1230-02-08-elispot-final

Latest Resources

See all resources